RANCHO CORDOVA, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) today announced that Joe Balagot, senior vice president of corporate development, will present an overview of the company, with a focus on its automated, closed systems for manufacturing CAR-T and other cell therapies, at the BIO-Europe Spring 12th Annual International Partnering Conference, which is being held March 12-14 at the Amsterdam RAI Convention Center in Amsterdam, The Netherlands.
Mr. Balagot’s presentation is scheduled to take place on Tuesday, March 13 at 3:30pm CET in Room E106.
With a focus on European innovation and global collaboration, BIO-Europe Spring 2018 is the premier springtime partnering conference bringing together executives from biotech, pharma and finance in the most innovative biopharma clusters in Europe. For more information about the conference, go to: https://ebdgroup.knect365.com/bioeurope-spring/
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Cesca Therapeutics Inc.
Source: Cesca Therapeutics Inc.